Protalix BioTherapeutics Files 8-K

TL;DR

PLX filed an 8-K, likely containing financial updates or disclosures.

AI Summary

On October 25, 2024, Protalix BioTherapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Protalix BioTherapeutics is providing updates or disclosures to the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific material information that would indicate a high risk.

Key Players & Entities

• Protalix BioTherapeutics, Inc. (company) — Registrant
• October 25, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 001-33357 (filing_id) — SEC File Number
• 65-0643773 (tax_id) — IRS Employer Identification No.
• 2 University Plaza, Suite 100, Hackensack, NJ 07601 (address) — Business and Mail Address

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common stock, $0.001 par value PLX NYSE American Indic

Filing Documents

• plx-20241025x8k.htm (8-K) — 38KB
• plx-20241025xex99d1.htm (EX-99.1) — 15KB
• plx-20241025xex99d1001.jpg (GRAPHIC) — 5KB
• 0001558370-24-013664.txt ( ) — 184KB
• plx-20241025.xsd (EX-101.SCH) — 3KB
• plx-20241025_lab.xml (EX-101.LAB) — 16KB
• plx-20241025_pre.xml (EX-101.PRE) — 11KB
• plx-20241025x8k_htm.xml (XML) — 5KB

01

Item 7.01 Regulation FD Disclosure On October 25, 2024, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing that data from the phase I clinical trial of PRX-115, the Company's recombinant PEGylated uricase product candidate in development for the treatment of uncontrolled gout, will be presented in a late-breaking poster at the American College of Rheumatology (ACR) Convergence 2024, being held November 14-19, 2024 at the Walter E. Washington Convention Center in Washington, D.C. The press release also disclosed that an abstract containing data generated in the trial may be accessed on the ACR Convergence 2024 website at https://acrabstracts.org/abstract/prolonged-plasma-urate-lowering-after-a-single-intravenous-administration-of-prx-115-a-novel-pegylated-uricase-in-participants-with-elevated-urate-levels/. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K ("Current Report"). In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated October 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 25, 2024 PROTALIX BIOTHERAPEUTICS, INC. By: /s/ Dror Bashan Name: Dror Bashan Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR